Two Indexes.
Two Distinct Biotech Exposures.

LifeSci Index Partners provides rules-based, science-first indexes covering the full biotechnology drug development lifecycle.

Explore Our Indexes →

Our Indexes

Two complementary lenses on the biotechnology sector — from FDA-approved commercial stage to clinical-stage pipeline innovation.

LSCIBP

LifeSci Biotechnology Products Index

Commercial-Stage Biotech

Tracks U.S.-listed pure biotech companies with at least one FDA-approved drug therapy. 61 components. Equal weight. Semi-annual reconstitution.

61 Components $4.3B Median Mkt Cap (12/31/25) Equal Weight

LSCIBC

LifeSci Biotechnology Clinical Trials Index

Clinical-Stage Biotech

Tracks U.S.-listed pure biotech companies with a lead drug in Phase 1, 2, or 3 clinical trials. 124 components. Equal weight. Semi-annual reconstitution.

124 Components $1.4B Median Mkt Cap (12/31/25) Equal Weight

Why Biotech Now

Three structural forces are reshaping biotechnology investment.

🧬The Silver Tsunami

Aging demographics across developed economies are driving unprecedented healthcare demand. By 2030, all Baby Boomers will be over 65 — accelerating the need for novel therapies across oncology, neurology, and rare disease.

📊The Patent Cliff

$236B+ in branded pharmaceutical revenue is at risk through 2030 as key patents expire, forcing Big Pharma to acquire biotech innovation to replenish their pipelines. M&A premiums for clinical and commercial-stage biotechs remain elevated.

🔬The Science Revolution

Biotechnology now accounts for over 70% of FDA novel drug approvals. Breakthroughs in gene therapy, mRNA platforms, and AI-accelerated drug discovery are compressing development timelines and expanding the addressable market.

What Leaders Are Saying

“I’m positive on biotech… my instinct is we’re about to cure a lot of diseases.”

Dario Amodei, CEO Anthropic (MD/PhD)
People by WTF Podcast, February 2026

“We’ve now invested over $60 billion since 2021 in business development … But, importantly, we’re not done. We have more to do.”

Robert Davis, Chairman & CEO Merck
J.P. Morgan Healthcare Conference, January 2026

Annual Returns (2016–2025)

Calendar-year total return for each LifeSci index.

Past performance is not indicative of future results. One cannot invest directly in an index. Source: LifeSci Index Partners / Indxx, Inc.

Part of the LifeSci Ecosystem

LifeSci Index Partners is an affiliate of LifeSci Partners, a leading investment bank focused exclusively on life sciences. Our indexes are built on the same sector expertise and scientific rigor that drives LifeSci Partners’ advisory and capital markets work.

Contact

For index data requests, licensing inquiries, or general questions, reach us at info@lifesci-index.com.

Two Indexes.Two Distinct Biotech Exposures.